CANN GROUP LIMITED — Capital/Financing Update 2019

Apr 16, 2019

==> picture [585 x 60] intentionally omitted <==

ASX ANNOUNCEMENT

17 APRIL 2019

RELEASE FROM ASX ESCROW

Cann Group Limited (the “Company”) advises that in accordance with ASX Listing Rule 3.10A 32,720,001 fully paid ordinary shares will be released from escrow on 6 May 2019.

The Company will apply for quotation of these shares on 6 May 2019.

The Company confirms that the Directors and the CEO hold a total of 9,211,682 shares subject to the current escrow and, at this stage, do not intend trading any of those shares upon release from escrow.

For further information please contact: Peter Crock Matthew Wright Cann Group Limited NWR Communications +61 (0) 3 9095 7088 +61 (0) 451 896 420 contact@canngrouplimited.com matt@nwrcommunications.com.au

About Cann Group

Cann Group is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia. The company has established research and cultivation facilities in Melbourne and is striving to provide access to medicinal cannabis for Australian patients. Cann Group has executed collaboration agreements that will enable it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. It was issued with Australia’s first medicinal cannabis research licence in February 2017, in addition to Australia’s first medicinal cannabis cultivation licence in March 2017. Aurora Cannabis Inc – one of Canada’s largest listed medicinal cannabis companies – is a cornerstone investor in Cann, with a 22.9% shareholding.

==> picture [595 x 78] intentionally omitted <==